Inhaled corticosteroids (ICS) combined with bronchodilators can reduce the frequency of
exacerbations in some patients with chronic obstructive pulmonary disease (COPD). There …

Current guidelines for the management of chronic obstructive pulmonary disease (COPD)
recommend limiting the use of inhaled corticosteroids (ICS) to patients with more severe …

The efficacy, safety and positioning of inhaled corticosteroids (ICS) in the treatment of
patients with chronic obstructive pulmonary disease (COPD) is much debated, since it can …

Inhaled corticosteroids (ICS) reduce COPD exacerbation frequency and slow decline in
health related quality of life but have little effect on lung function, do not reduce mortality, and …

Background Guidelines recommend inhaled corticosteroids (ICS) for patients with severe
chronic obstructive pulmonary disease (COPD). Most COPD patients are managed in …

Background It has been suggested that withdrawal of inhaled corticosteroids (ICS) in COPD
patients on maintenance treatment results in deterioration of symptoms, lung function and …

The recent Towards a Revolution in COPD Health (TORCH) randomised trial replicated the
findings of previous trials in chronic obstructive pulmonary disease (COPD) on the apparent …

In this article, we focus on the scientific evidence from randomised trials supporting
treatment with inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease …

Background Inhaled corticosteroids (ICS) have been shown to decrease the occurrence of
COPD exacerbations. However, the relationship of baseline lung function and reduction of …

Background The role of inhaled corticosteroids (ICS) in chronic obstructive pulmonary
disease (COPD) has been the subject of much controversy. Major international guidelines …